Consolidated Statements of Equity - USD ($) $ in Thousands |
Total |
EirGen Pharma Limited |
Bio-Reference Laboratories, Inc. |
OPKO Brazil |
OPKO Renal |
OPKO Biologics |
OPKO Health Europe |
OPKO Uruguay Ltda. |
Inspiro |
Common Stock |
Common Stock
EirGen Pharma Limited
|
Common Stock
Bio-Reference Laboratories, Inc.
|
Common Stock
OPKO Brazil
|
Common Stock
OPKO Renal
|
Common Stock
OPKO Biologics
|
Common Stock
OPKO Health Europe
|
Treasury |
Treasury
OPKO Health Europe
|
Treasury
OPKO Uruguay Ltda.
|
Treasury
Inspiro
|
Additional Paid-In Capital |
Additional Paid-In Capital
EirGen Pharma Limited
|
Additional Paid-In Capital
Bio-Reference Laboratories, Inc.
|
Additional Paid-In Capital
OPKO Brazil
|
Additional Paid-In Capital
OPKO Renal
|
Additional Paid-In Capital
OPKO Biologics
|
Additional Paid-In Capital
OPKO Health Europe
|
Additional Paid-In Capital
OPKO Uruguay Ltda.
|
Additional Paid-In Capital
Inspiro
|
Accumulated Other Comprehensive Income (Loss) |
Accumulated Deficit |
Noncontrolling Interests |
Series D Preferred Stock |
Series D Preferred Stock
Common Stock
|
Series D Preferred Stock
Additional Paid-In Capital
|
Notes |
Notes
Common Stock
|
Notes
Additional Paid-In Capital
|
|||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Beginning balance at Dec. 31, 2012 | $ 178,894 | $ 3,056 | $ (7,457) | $ 565,201 | $ 7,356 | $ (388,770) | $ (492) | ||||||||||||||||||||||||||||||||||
Beginning balance, shares at Dec. 31, 2012 | 305,560,763 | (2,293,056) | |||||||||||||||||||||||||||||||||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||||||||||||||||||||||||||||||||||
Equity-based compensation expense | 10,983 | 10,983 | |||||||||||||||||||||||||||||||||||||||
Exercise of Common Stock options and warrants | 23,424 | $ 107 | 23,317 | ||||||||||||||||||||||||||||||||||||||
Exercise of Common Stock options, shares | 10,732,745 | ||||||||||||||||||||||||||||||||||||||||
Preferred Stock dividend | $ (3,015) | $ (3,015) | |||||||||||||||||||||||||||||||||||||||
Conversion of Preferred Stock | $ 24,386 | $ 113 | $ 24,273 | $ 20,839 | $ 24 | $ 20,815 | |||||||||||||||||||||||||||||||||||
Conversion of Preferred Stock, shares | 11,290,320 | 2,396,145 | |||||||||||||||||||||||||||||||||||||||
Issuance of Common Stock in connection with acquisition | $ 435 | $ 146,902 | $ 586,643 | $ 1 | $ 205 | $ 637 | $ 434 | $ 146,697 | $ 586,006 | ||||||||||||||||||||||||||||||||
Issuance of Common Stock in connection with acquisition, shares | 64,684 | 20,517,030 | 63,670,805 | ||||||||||||||||||||||||||||||||||||||
Issuance of Common Stock in connection with Deferred Payment | $ 4,435 | $ 5 | $ 4,430 | ||||||||||||||||||||||||||||||||||||||
Issuance of Common Stock in connection with Deferred Payment, shares | 585,703 | ||||||||||||||||||||||||||||||||||||||||
Issuance of Treasury Stock in connection with Contingent Consideration | 337 | $ 95 | 242 | ||||||||||||||||||||||||||||||||||||||
Issuance of Treasury Stock in connection with Contingent Consideration, shares | 28,993 | ||||||||||||||||||||||||||||||||||||||||
Net loss attributable to common shareholders | (114,407) | (114,407) | |||||||||||||||||||||||||||||||||||||||
Net loss attributable to noncontrolling interests | (2,939) | (2,939) | |||||||||||||||||||||||||||||||||||||||
Other comprehensive loss | (3,938) | (3,938) | |||||||||||||||||||||||||||||||||||||||
Ending balance at Dec. 31, 2013 | 872,979 | $ 4,148 | $ (7,362) | 1,379,383 | 3,418 | (503,177) | (3,431) | ||||||||||||||||||||||||||||||||||
Ending balance, shares at Dec. 31, 2013 | 414,818,195 | (2,264,063) | |||||||||||||||||||||||||||||||||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||||||||||||||||||||||||||||||||||
Equity-based compensation expense | 14,737 | 14,737 | |||||||||||||||||||||||||||||||||||||||
Exercise of Common Stock options and warrants | 12,928 | $ 54 | 12,874 | ||||||||||||||||||||||||||||||||||||||
Exercise of Common Stock options, shares | 5,392,841 | ||||||||||||||||||||||||||||||||||||||||
Issuance of Common Stock in connection with acquisition | 95,665 | 21,155 | $ 159 | $ 8,566 | $ 110 | $ 22 | $ 61 | $ 3,250 | 95,555 | 21,133 | $ 98 | $ 5,316 | |||||||||||||||||||||||||||||
Issuance of Common Stock in connection with acquisition, shares | 10,974,431 | 2,236,210 | 19,140 | 999,556 | |||||||||||||||||||||||||||||||||||||
Net loss attributable to common shareholders | (171,666) | (171,666) | |||||||||||||||||||||||||||||||||||||||
Net loss attributable to noncontrolling interests | (2,972) | (2,972) | |||||||||||||||||||||||||||||||||||||||
Other comprehensive loss | (15,810) | (15,810) | |||||||||||||||||||||||||||||||||||||||
Ending balance at Dec. 31, 2014 | 835,741 | [1] | $ 4,334 | $ (4,051) | 1,529,096 | (12,392) | (674,843) | (6,403) | |||||||||||||||||||||||||||||||||
Ending balance, shares at Dec. 31, 2014 | 433,421,677 | (1,245,367) | |||||||||||||||||||||||||||||||||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||||||||||||||||||||||||||||||||||
Equity-based compensation expense | 26,074 | 26,074 | |||||||||||||||||||||||||||||||||||||||
Exercise of Common Stock options and warrants | $ 25,920 | $ 245 | 25,675 | ||||||||||||||||||||||||||||||||||||||
Exercise of Common Stock options, shares | 6,643,991 | 24,467,806 | |||||||||||||||||||||||||||||||||||||||
Issuance of Common Stock in connection with acquisition | $ 120,299 | $ 33,596 | $ 950,010 | $ 20,112 | $ 81 | $ 24 | $ 766 | $ 12 | 120,218 | $ 33,572 | $ 949,244 | $ 20,100 | |||||||||||||||||||||||||||||
Issuance of Common Stock in connection with acquisition, shares | 8,118,062 | 2,420,487 | 76,566,147 | 1,194,337 | |||||||||||||||||||||||||||||||||||||
Issuance of Treasury Stock in connection with Contingent Consideration | $ 1,812 | $ 406 | $ 1,406 | ||||||||||||||||||||||||||||||||||||||
Issuance of Treasury Stock in connection with Contingent Consideration, shares | 125,000 | ||||||||||||||||||||||||||||||||||||||||
Net loss attributable to common shareholders | (30,028) | (30,028) | |||||||||||||||||||||||||||||||||||||||
Deconsolidation of SciVac | 6,403 | 6,403 | |||||||||||||||||||||||||||||||||||||||
Net loss attributable to noncontrolling interests | (1,400) | ||||||||||||||||||||||||||||||||||||||||
Other comprehensive loss | (10,145) | (10,145) | |||||||||||||||||||||||||||||||||||||||
Ending balance at Dec. 31, 2015 | $ 1,979,794 | [1] | $ 5,462 | $ (3,645) | $ 2,705,385 | $ (22,537) | $ (704,871) | $ 0 | |||||||||||||||||||||||||||||||||
Ending balance, shares at Dec. 31, 2015 | 546,188,516 | (1,120,367) | |||||||||||||||||||||||||||||||||||||||
|